Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine
Link
http://www.nature.com/articles/hr2014118.pdf
Reference9 articles.
1. Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K . Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013; 19: 3002–3008.
2. Miura S, Karnik SS, Saku K . Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12: 1–7.
3. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–392.
4. Rakugi H, Enya K, Sugiura K, Ikeda Y . Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552–558.
5. Takahara M, Shiraiwa T, Shindo M, Arai A, Kusuda Y, Katakami N, Kaneto H, Matsuoka T, Shimomura I . Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. Hypertens Res 2014; 37: 852–857.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A comprehensive review of recent advances in the biological activities of 1,2,4‐oxadiazoles;Archiv der Pharmazie;2022-04-21
2. 1,2,4-Oxadiazoles;Comprehensive Heterocyclic Chemistry IV;2022
3. Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People;Clinical Pharmacology in Drug Development;2021-07-08
4. RECENT ADVANCES ON 1,2,4-OXADIAZOLES: FROM SYNTHESIS TO REACTIVITY AND PHARMACEUTICAL APPLICATIONS;TARG HETEROCYCL SYST;2020
5. Drug nanoclusters formed in confined nano-cages of CD-MOF: dramatic enhancement of solubility and bioavailability of azilsartan;Acta Pharmaceutica Sinica B;2019-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3